CompletedPhase 3

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Australia2,417 participantsStarted 2010-05

Plain-language summary

This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18-65 years of age, must have relapsing MS Exclusion Criteria: * Patients with a type of MS that is not relapsing * Patients with history of chronic immune disease * Patients with a history of certain cancers * Diabetic patients with certain eye disorders * Patients who are on certain immunosuppressive medications or heart medications * Patients with certain heart conditions * Patients with certain lung conditions Other protocol-defined inclusion/exclusion criteria may apply.

What they're measuring

Evaluate the safety and tolerability profile of FTY720 in patients with relapsing forms of MS

Timeframe: 4 months

Trial details

NCT IDNCT01127750

SponsorNovartis

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-10

View on ClinicalTrials.gov More Relapsing Multiple Sclerosis trials